
Sign up to save your podcasts
Or


Systemic lupus erythematosus (SLE) can present at any age and is associated with immune-mediated damage to multiple organs and increased rates of cardiovascular disease, cancer, and disability. New treatments have been FDA approved. Caroline H. Siegel, MD, MS, discusses this and more with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content:
By JAMA Network4.4
471471 ratings
Systemic lupus erythematosus (SLE) can present at any age and is associated with immune-mediated damage to multiple organs and increased rates of cardiovascular disease, cancer, and disability. New treatments have been FDA approved. Caroline H. Siegel, MD, MS, discusses this and more with JAMA Deputy Editor Mary McGrae McDermott, MD. Related Content:

136 Listeners

316 Listeners

696 Listeners

162 Listeners

883 Listeners

296 Listeners

260 Listeners

3,346 Listeners

38 Listeners

272 Listeners

21 Listeners

12 Listeners

11 Listeners

9 Listeners

16 Listeners

19 Listeners

5 Listeners

7 Listeners

1,147 Listeners

30 Listeners

193 Listeners

9 Listeners

94 Listeners

14 Listeners

5 Listeners

514 Listeners

5 Listeners

367 Listeners

428 Listeners

106 Listeners

18 Listeners

370 Listeners

3 Listeners

273 Listeners